Safety and tolerability of subcutaneous PTHrP(1–36) in healthy human volunteers: a dose escalation study

@article{Horwitz2005SafetyAT,
  title={Safety and tolerability of subcutaneous PTHrP(1–36) in healthy human volunteers: a dose escalation study},
  author={Mara J. Horwitz and Mary Beth Tedesco and Susan M. Sereika and Adolfo Garcia-Oca{\~n}a and Alessandro Bisello and Bruce W. Hollis and Caren M. Gundberg and Andrew Francis Stewart},
  journal={Osteoporosis International},
  year={2005},
  volume={17},
  pages={225-230}
}
Parathyroid hormone-related protein (PTHrP) is an anabolic skeletal agent in mice, rats and humans. In previous studies, we have demonstrated that PTHrP can be administered to osteoporotic postmenopausal women at a dose of 6.56 ug/kg/day (or approximately 400 ug/day) for 3 months to yield a 4.7% increase in lumbar spine BMD. This regimen was free of hypercalcemia or adverse effects. Moreover, PTHrP appeared to stimulate bone formation selectively, without stimulating bone resorption. This… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Six month daily administration of PTH and PTHrP peptides to adult ovariectomized rats markedly enhances bone mass and biomechanics: a comparison of human PTH(1–34), PTHrP(1–36) and SDZ-PTH-893

  • AF Stewart, RL Cain, DB Burr, CH Turner, JM Hock
  • J Bone Min Res
  • 2000
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…